Therapeutic angiogenesis by gene therapy for critical limb ischemia: Choice of biological agent

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 32-39

  Sanada, Fumihiro ^a   Taniyama, Yoshiaki ^a   Azuma, Junya ^a   Yuka, Ikeda Iwabe ^a   Kanbara, Yasuhiro ^a   Iwabayashi, Masaaki ^a   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical limb ischemia; Fibroblast growth factor; Gene therapy; Hepatocyte growth factor; Peripheral artery disease; Therapeutic angiogenesis; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL PRODUCT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; PLACEBO; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; APOPTOSIS; ARTICLE; CRITICAL LIMB ISCHEMIA; FIBROSIS; GENE EXPRESSION; HUMAN; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SENESCENCE; VASCULAR REMODELING;

EID: 84906914798     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/1871522213999131231105139     Document Type: Review

References (77)

1. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; Al-varado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Barker-Collo, S.; Bartels, D.H.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bhalla, K.; Bikbov, B.; Bin, Abdulhak, A.; Birbeck, G.; Blyth, F.; Bolliger, I.; Boufous, S.; Bucello, C.; Burch, M.; Burney, P.; Carapetis, J.; Chen, H.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Col-son, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C.; Dahodwala, N.; De Leo, D.; Degenhardt, L.; Delossantos, A.; Denenberg, J.; Des Jarlais, D.C.; Dharmaratne, S.D.; Dorsey, E.R.; Driscoll, T.; Duber, H.; Ebel, B.; Erwin, P.J.; Espindola, P.; Ezzati, M.; Feigin, V.; Flaxman, A.D.; Forouzanfar, M.H.; Fowkes, F.G.; Franklin, R.; Fransen, M.; Freeman, M.K.; Gabriel, S.E.; Gakidou, E.; Gaspari, F.; Gillum, R.F.; Gonzalez-Medina, D.; Halasa, Y.A.; Haring, D.; Harrison, J.E.; Havmoeller, R.; Hay, R.J.; Hoen, B.; Hotez, P.J.; Hoy, D.; Jacob-sen, K.H.; James, S.L.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Karthikeyan, G.; Kassebaum, N.; Keren, A.; Khoo, J.P.; Knowlton, L.M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Lipnick, M.; Lipshultz, S.E.; Ohno, S.L.; Mabweijano, J.; MacIntyre, M.F.; Mallinger, L.; March, L.; Marks, G.B.; Marks, R.; Matsumori, A.; Matzopoulos, R.; Mayosi, B.M.; McAnulty, J.H.; McDermott, M.M.; McGrath, J.; Mensah, G.A.; Merriman, T.R.; Michaud, C.; Miller, M.; Miller, T.R.; Mock, C.; Mocumbi, A.O.; Mokdad, A.A.; Moran, A.; Mulholland, K.; Nair, M.N.; Naldi, L.; Narayan, K.M.; Nasseri, K.; Norman, P.; O'Donnell, M.; Omer, S.B.; Ortblad, K.; Osborne, R.; Ozgediz, D.; Pahari, B.; Pandian, J.D.; Rivero, A.P.; Padilla, R.P.; Perez-Ruiz, F.; Perico, N.; Phillips, D.; Pierce, K.; Pope, C.A. 3rd.; Porrini, E.; Pourmalek, F.; Raju, M.; Ranganathan, D.; Rehm, J.T.; Rein, D.B.; Remuzzi, G.; Rivara, F.P.; Roberts, T.; De Leon, F.R.; Rosenfeld, L.C.; Rushton, L.; Sacco, R.L.; Salomon, J.A.; Sampson, U.; Sanman, E.; Schwebel, D.C.; Segui-Gomez, M.; Shepard, D.S.; Singh, D.; Singleton, J.; Sliwa, K.; Smith, E.; Steer, A.; Taylor, J.A.; Thomas, B.; Tleyjeh, I.M.; Tow-bin, J.A.; Truelsen, T.; Undurraga, E.A.; Venketasubramanian, N.; Vijayakumar, L.; Vos, T.; Wagner, G.R.; Wang, M.; Wang, W.; Watt, K.; Weinstock, M.A.; Weintraub, R.; Wilkinson, J.D.; Woolf, A.D.; Wulf, S.; Yeh, P.H.; Yip, P.; Zabetian, A.; Zheng, Z.J.; Lopez, A.D.; Murray, C.J.; AlMazroa, M.A.; Memish, Z.A. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet, 2012, 380(9859), 2095-2128.
2. Fowkes, F.G.; Rudan, D.; Rudan, I.; Aboyans, V.; Denenberg, J.O.; McDermott, M.M.; Norman, P.E.; Sampson, U.K.; Williams, L.J.; Mensah, G.A.; Criqui, M.H. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet, 2013, 382(9901), 1329-1340.
3. Belch, J.J.; Topol, E.J.; Agnelli, G.; Bertrand, M.; Califf, R.M.; Clement, D.L.; Creager, M.A.; Easton, J.D.; Gavin, J.R. 3rd.; Greenland, P.; Hankey, G.; Hanrath, P.; Hirsch, A.T.; Meyer, J.; Smith, S.C.; Sullivan, F.; Weber, M.A. Critical issues in peripheral arterial disease detection and management: A call to action. Arch. Intern. Med., 2003, 163(8), 884-892.
4. Norgren, L.; Hiatt, W.R.; Dormandy, J.A.; Nehler, M.R.; Harris, K.A.; Fowkes, F.G. Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg., 2007, 45(Suppl. S), S5-67.
5. Beckman, J.A.; Creager, M.A.; Libby, P. Diabetes and atheroscle-rosis: Epidemiology, pathophysiology, and management. JAMA, 2002, 287(19), 2570-2581.
6. Lau, J.F.; Weinberg, M.D.; Olin, J.W. Peripheral artery disease. Part 1: Clinical evaluation and noninvasive diagnosis. Nat. Rev. Cardiol., 2011, 8(7), 405-418.
7. Hiatt, W.R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med., 2001, 344(21), 1608-1621.
8. Annex, B.H. Therapeutic angiogenesis for critical limb ischaemia. Nat. Rev. Cardiol., 2013, 10(7), 387-396.
9. Hankey, G.J.; Norman, P.E.; Eikelboom, J.W. Medical treatment of peripheral arterial disease. JAMA, 2006, 295(5), 547-553.
10. Hirsch, A.T.; Haskal, Z.J.; Hertzer, N.R.; Bakal, C.W.; Creager, M.A.; Halperin, J.L.; Hiratzka, L.F.; Murphy, W.R.; Olin, J.W.; Puschett, J.B.; Rosenfield, K.A.; Sacks, D.; Stanley, J.C.; Taylor, L.M. Jr.; White, C.J.; White, J.; White, R.A.; Antman, E.M.; Smith, S.C. Jr.; Adams, C.D.; Anderson, J.L.; Faxon, D.P.; Fuster, V.; Gibbons, R.J.; Hunt, S.A.; Jacobs, A.K.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B. Acc/aha 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-society Consensus; and Vascular Disease Foundation. J. Am. Coll. Car-diol., 2006, 47(6),1239-1312.
11. Rastan, A.; Tepe, G.; Krankenberg, H.; Zahorsky, R.; Beschorner, U.; Noory, E.; Sixt, S.; Schwarz, T.; Brechtel, K.; Bohme, C.; Neumann, F.J.; Zeller, T. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: A double-blind, multi-centre, randomized clinical trial. Eur. Heart J., 2011, 32(18), 2274-2281.
12. Blum, A.; Balkan, W.; Hare, J.M. Advances in cell-based therapy for peripheral vascular disease. Atherosclerosis, 2012, 223(2), 269-277.
13. Baumgartner, I.; Pieczek, A.; Manor, O.; Blair, R.; Kearney, M.; Walsh, K.; Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation, 1998, 97(12), 1114-1123.
14. Comerota, A.J.; Throm R.C.; Miller, K.A.; Henry, T.; Chronos, N.; Laird, J.; Sequeira, R.; Kent, C.K.; Bacchetta, M.; Goldman, C.; Salenius, J.P.; Schmieder, F.A.; Pilsudski, R. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial. J. Vasc. Surg., 2002, 35(5), 930-936.
15. Kusumanto, Y.H.; van Weel, V.; Mulder, N.H.; Smit, A.J.; van den Dungen, J.J.; Hooymans, J.M.; Sluiter, W.J.; Tio, R.A.; Quax, P.H.; Gans, R.O.; Dullaart, R.P.; Hospers, G.A. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum. Gene Ther., 2006, 17(6), 683-691.
16. Belch, J.; Hiatt, W.R.; Baumgartner, I.; Driver, I.V.; Nikol, S.; Norgren, L.; Van Belle, E. Effect of fibroblast growth factor NV1 FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet, 2011, 377(9781), 1929-1937.
17. Powell, R.J.; Simons, M.; Mendelsohn, F.O.; Daniel, G.; Henry, T.D.; Koga, M.; Morishita, R.; Annex, B.H. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb per-fusion in patients with critical limb ischemia. Circulation, 2008, 118(1), 58-65.
18. Shigematsu, H.; Yasuda, K.; Iwai, T.; Sasajima, T.; Ishimaru, S.; Ohashi, Y.; Yamaguchi, T.; Ogihara, T.; Morishita, R. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther., 2010, 17(9), 1152-1161.
19. Scholz, D.; Ziegelhoeffer, T.; Helisch, A.; Wagner, S.; Friedrich, C.; Podzuweit, T.; Schaper, W. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J. Mol. Cell. Cardiol., 2002, 34(7), 775-787.
20. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997, 275(5302), 964-967.
21. Gunsilius, E.; Duba, H.C.; Petzer, A.L.; Kahler, C.M.; Grunewald, K.; Stockhammer, G.; Gabl, C.; Dirnhofer, S.; Clausen, J.; Gastl, G. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet, 2000, 355(9216), 1688-1691.
22. Muhlhauser, J.; Merrill, M.J.; Pili, R.; Maeda, H.; Bacic, M.; Be-wig, B.; Passaniti, A.; Edwards, N.A.; Crystal, R.G.; Capogrossi, M.C. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ. Res., 1995, 77(6), 1077-1086.
23. Gowdak, L.H.; Poliakova, L.; Wang, X.; Kovesdi, I.; Fishbein, K.W.; Zacheo, A.; Palumbo, R.; Straino, S.; Emanueli, C.; Mar-rocco-Trischitta, M.; Lakatta, E.G.; Anversa, P.; Spencer, R.G.; Ta-lan, M.; Capogrossi, M.C. Adenovirus-mediated VEGF (121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation, 2000, 102(5), 565-571.
24. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358(19), 2039-2049.
25. Isner, J.M. Therapeutic angiogenesis: A new frontier for vascular therapy. Vasc. Med., 1996, 1(1), 79-87.
26. Takahashi, H.; Shibuya, M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond)., 2005, 109(3), 227-241.
27. Takeshita, S.; Zheng, L.P.; Brogi, E.; Kearney, M.; Pu, L.Q.; Bunting, S.; Ferrara, N.; Symes, J.F.; Isner, J.M. Therapeutic angio-genesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest., 1994, 93(2), 662-670.
28. Walder, C.E.; Errett, C.J.; Bunting, S.; Lindquist, P.; Ogez, J.R.; Heinsohn, H.G.; Ferrara, N.; Thomas, G.R. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J. Cardiovasc. Pharmacol., 1996, 27(1), 91-98.
29. Kalka, C.; Tehrani, H.; Laudenberg, B.; Vale, P.R.; Isner, J.M.; Asahara, T.; Symes, J.F. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann. Thorac. Surg., 2000, 70(3), 829-834.
30. Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwa-guro, H.; Inai, Y.; Silver, M.; Isner, J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J., 1999, 18(14), 3964-3972.
31. Makinen, K.; Manninen, H.; Hedman, M.; Matsi, P.; Mussalo, H.; Alhava, E.; Yla-Herttuala, S. Increased vascularity detected by digital subtraction angiography after vegf gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol. Ther., 2002, 6(1), 127-133.
32. Rajagopalan, S.; Mohler, E. 3rd. Lederman, R.J.; Saucedo, J.; Mendelsohn, F.O.; Olin, J.; Blebea, J.; Goldman, C.; Trachtenberg, J.D.; Pressler, M.; Rasmussen, H.; Annex, B.H.; Hirsch, A.T. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the rave trial. Am. Heart. J., 2003, 145(6), 1114-1118.
33. Monaghan-Benson, E.; Burridge, K. The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J. Biol. Chem., 2009, 284(38), 25602-25611.
34. Ehrbar, M.; Djonov, V.G.; Schnell, C.; Tschanz, S.A.; Martiny-Baron, G.; Schenk, U.; Wood, J.; Burri, P.H.; Hubbell, J.A.; Zisch, A.H. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res., 2004, 94(8), 1124-1132.
35. Burger, P.E.; Coetzee, S.; McKeehan, W.L.; Kan, M.; Cook, P.; Fan, Y.; Suda, T.; Hebbel, R.P.; Novitzky, N.; Muller, W.A.; Wilson, E.L. Fibroblast growth factor receptor-1 is expressed by endo-thelial progenitor cells. Blood, 2002, 100(10), 3527-3535.
36. Goncalves, L.M. Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev. Port. Cardiol., 1998, 17(Suppl. 2), II11-II20.
37. Nikol, S.; Baumgartner, I.; Van Belle, E.; Diehm, C.; Visona, A.; Capogrossi, M.C.; Ferreira-Maldent, N.; Gallino, A.; Wyatt, M.G.; Wijesinghe, L.D.; Fusari, M.; Stephan, D.; Emmerich, J.; Pompilio, G.; Vermassen, F.; Pham, E.; Grek, V.; Coleman, M.; Meyer, F. Therapeutic angiogenesis with intramuscular NV1 FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther., 2008, 16(5), 972-978.
38. Nakamura, T.; Teramoto, H.; Ichihara, A. Purification and characterization of a growth factor from rat platelets for mature paren-chymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA, 1986, 83(17), 6489-6493.
39. Wojakowski, W.; Tendera, M.; Michalowska, A.; Majka, M.; Kucia, M.; Maslankiewicz, K.; Wyderka, R.; Ochala, A.; Rata-jczak, MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation, 2004, 110(20), 3213-3220.
40. Morishita, R.; Aoki, M.; Hashiya, N.; Makino, H.; Yamasaki, K.; Azuma, J.; Sawa, Y.; Matsuda, H.; Kaneda, Y.; Ogihara, T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension, 2004, 44(2), 203-209.
41. Makino, H.; Aoki, M.; Hashiya, N.; Yamasaki, K.; Azuma, J.; Sawa, Y.; Kaneda, Y.; Ogihara, T.; Morishita, R. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arte-rioscler. Thromb. Vasc. Biol., 2012, 32(10), 2503-2509.
42. Coggan, A.R.; Spina, R.J.; King, D.S.; Rogers, M.A.; Brown, M.; Nemeth, P.M.; Holloszy, J.O. Skeletal muscle adaptations to endurance training in 60- to 70-yr-old men and women. J. Appl. Physiol. (1985)., 1992, 72(5), 1780-1786.
43. Selvin, E.; Erlinger, T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the national health and nutrition examination survey, 1999-2000. Circulation, 2004, 110(6), 738-743.
44. Robbins, J.L.; Jones, W.S.; Duscha, B.D.; Allen, J.D.; Kraus, W.E.; Regensteiner, J.G.; Hiatt, W.R.; Annex, B.H. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J. Appl. Physiol., 2011, 111(1), 81-86.
45. Minamino, T.; Komuro, I. Vascular cell senescence: Contribution to atherosclerosis. Circ. Res., 2007, 100(1), 15-26.
46. Sanada, F.; Taniyama, Y.; Azuma, J.; Iekushi, K.; Dosaka, N.; Yokoi, T.; Koibuchi, N.; Kusunoki, H.; Aizawa, Y.; Morishita, R. Hepatocyte growth factor, but not vascular endothelial growth fac-tor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension, 2009, 53(1), 77-82.
47. Sanada, F.; Taniyama, Y.; Iekushi, K.; Azuma, J.; Okayama, K.; Kusunoki, H.; Koibuchi, N.; Doi, T.; Aizawa, Y.; Morishita, R. Negative action of hepatocyte growth factor/c-met system on an-giotensin ii signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ. Res., 2009, 105(7), 667-675.
48. Yokoi, T.; Fukuo, K.; Yasuda, O.; Hotta, M.; Miyazaki, J.; Take-mura, Y.; Kawamoto, H.; Ichijo, H.; Ogihara, T. Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by high glucose in endothelial cells. Diabetes, 2006, 55(6), 1660-1665.
49. Sasaki, M.; Ikeda, H.; Sato, Y.; Nakanuma, Y. Proinflammatory cytokine-induced cellular senescence of biliary epithelial cells is mediated via oxidative stress and activation of atm pathway: A culture study. Free. Radic. Res., 2008, 42(7), 625-632.
50. Iekushi, K.; Taniyama, Y.; Kusunoki, H.; Azuma, J.; Sanada, F.; Okayama, K.; Koibuchi, N.; Iwabayashi, M.; Rakugi, H.; Mor-ishita, R. Hepatocyte growth factor attenuates transforming growth factor-beta-angiotensin ii crosstalk through inhibition of the pten/akt pathway. Hypertension, 2011, 58(2), 190-196.
51. Koibuchi, N.; Kaneda, Y.; Taniyama, Y.; Matsumoto, K.; Naka-mura, T.; Ogihara, T.; Morishita, R. Essential role of HGF (hepato-cyte growth factor) in blood formation in xenopus. Blood, 2004, 103(9), 3320-3325.
52. Taniyama, Y.; Morishita, R.; Nakagami, H.; Moriguchi, A.; Sa-konjo, H.; Shokei, K.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Potential contribution of a novel antifibrotic factor, he-patocyte growth factor, to prevention of myocardial fibrosis by an-giotensin II blockade in cardiomyopathic hamsters. Circulation, 2000, 102(2), 246-252.
53. Taniyama, Y.; Morishita, R.; Aoki, M.; Hiraoka, K.; Yamasaki, K.; Hashiya, N.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension, 2002, 40(1), 47-53.
54. Ueki, T.; Kaneda, Y.; Tsutsui, H.; Nakanishi, K.; Sawa, Y.; Mor-ishita, R.; Matsumoto, K.; Nakamura, T.; Takahashi, H.; Okamoto, E.; Fujimoto, J. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med., 1999, 5(2), 226-230.
55. Vlassara, H.; Cai, W.; Chen, X.; Serrano, E.J.; Shobha, MS.; Uri-barri, J.; Woodward, M.; Striker, G.E. Managing chronic inflammation in the aging diabetic patient with ckd by diet or sevelamer carbonate: A modern paradigm shift. J. Gerontol. A Biol. Sci. Med. Sci., 2012, 67(12), 1410-1416.
56. Hansson, GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352 (16), 1685-1695.
57. Mantzouranis, E.C.; Rosen, F.S.; Colten, H.R. Reticuloendothelial clearance in cystic fibrosis and other inflammatory lung diseases. N. Engl. J. Med., 1988, 319(6), 338-343.
58. Kuilman, T.; Michaloglou, C.; Vredeveld, L.C.; Douma, S.; van Doorn, R.; Desmet, C.J.; Aarden, L.A.; Mooi, W.J.; Peeper, D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 2008, 133(6), 1019-1031.
59. Chandeck, C.; Mooi, W.J. Oncogene-induced cellular senescence. Adv. Anat. Pathol., 2010, 17(1), 42-48.
60. Mooi, W.J. Oncogene-induced cellular senescence: Causal factor in the growth arrest of pituitary microadenomas? Horm. Res., 2009, 71(Suppl. 2), 78-81.
61. Imanishi, T.; Tsujioka, H.; Akasaka, T. Endothelial progenitor cell senescence--is there a role for estrogen? Ther. Adv. Cardiovasc. Dis., 2010, 4(1), 55-69.
62. Shimizu, K.; Taniyama, Y.; Sanada, F.; Azuma, J.; Iwabayashi, M.; Iekushi, K.; Rakugi, H.; Morishita, R. Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation. Arterioscler. Thromb. Vasc. Biol., 2012, 32(11), 2687-2693.
63. Kaga, T.; Kawano, H.; Sakaguchi, M.; Nakazawa, T.; Taniyama, Y.; Morishita, R. Hepatocyte growth factor stimulated angiogenesis without inflammation: Differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibro-blast growth factor. Vasc. Pharmacol., 2012, 57(1), 3-9.
64. Ohtani, K.; Egashira, K.; Hiasa, K.; Zhao, Q.; Kitamoto, S.; Ishi-bashi, M.; Usui, M.; Inoue, S.; Yonemitsu, Y.; Sueishi, K.; Sata, M.; Shibuya, M.; Sunagawa, K. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation, 2004, 110(16), 2444-2452.
65. Van Belle, E.; Witzenbichler, B.; Chen, D.; Silver, M.; Chang, L.; Schwall, R.; Isner, J.M. Potentiated angiogenic effect of scatter fac-tor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogene-sis. Circulation, 1998, 97(4), 381-390.
66. Xin, X.; Yang, S.; Ingle, G.; Zlot, C.; Rangell, L.; Kowalski, J.; Schwall, R.; Ferrara, N.; Gerritsen, ME. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol., 2001, 158(3), 1111-1120.
67. Min, J.K.; Lee, Y.M.; Kim, J.H.; Kim, Y.M.; Kim, S.W.; Lee, S.Y.; Gho, Y.S.; Oh, G.T.; Kwon, Y.G. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial icam-1 and vcam-1 by inhibiting the nuclear factor-kappa B pathway. Circ. Res., 2005, 96(3), 300-307.
68. Hamada, N.; Kuwano, K.; Yamada, M.; Hagimoto, N.; Hiasa, K.; Egashira, K.; Nakashima, N.; Maeyama, T.; Yoshimi, M.; Naka-nishi, Y. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J. Immunol., 2005, 175(2), 1224-1231.
69. Chaudhary, N.I.; Roth, G.J.; Hilberg, F.; Muller-Quernheim, J.; Prasse, A.; Zissel, G.; Schnapp, A.; Park, J.E. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J., 2007, 29(5), 976-985.
70. Okayama, K.; Azuma, J.; Dosaka, N.; Iekushi, K.; Sanada, F.; Kusunoki, H.; Iwabayashi, M.; Rakugi, H.; Taniyama, Y.; Mor-ishita, R. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension, 2012, 59(5), 958-965.
71. Nakano, N.; Morishita, R.; Moriguchi, A.; Nakamura, Y.; Hayashi, S.I.; Aoki, M.; Kida, I.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Negative regulation of local hepatocyte growth factor expression by angiotensin ii and transforming growth factor-beta in blood vessels: Potential role of hgf in cardiovascular disease. Hypertension, 1998, 32(3), 444-451.
72. Urbanek, K.; Rota, M.; Cascapera, S.; Bearzi, C.; Nascimbene, A.; De Angelis, A.; Hosoda, T.; Chimenti, S.; Baker, M.; Limana, F.; Nurzynska, D.; Torella, D.; Rotatori, F.; Rastaldo, R.; Musso, E.; Quaini, F.; Leri, A.; Kajstura, J.; Anversa, P. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res., 2005, 97(7), 663-673.
73. Golomb, B.A.; Dang, T.T.; Criqui, M.H. Peripheral arterial disease: Morbidity and mortality implications. Circulation, 2006, 114(7), 688-699.
74. Dor, Y.; Djonov, V.; Abramovitch, R.; Itin, A.; Fishman, G.I.; Carmeliet, P.; Goelman, G.; Keshet, E. Conditional switching of VEGF provides new insights into adult neovascularization and pro angiogenic therapy. EMBO. J., 2002, 21(8), 1939-1947.
75. Gounis, M.J.; Spiga, M.G.; Graham, R.M.; Wilson, A.; Haliko, S.; Lieber, B.B.; Wakhloo, A.K.; Webster, K.A. Angiogenesis is confined to the transient period of VEGF expression that follows ade-noviral gene delivery to ischemic muscle. Gene. Ther., 2005, 12(9), 762-771.
76. Taniyama, Y.; Tachibana, K.; Hiraoka, K.; Namba, T.; Yamasaki, K.; Hashiya, N.; Aoki, M.; Ogihara, T.; Yasufumi, K.; Morishita, R. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation, 2002, 105(10), 1233-1239.
77. Fumoto, S.; Nishi, J.; Nakamura, J.; Nishida, K. Gene therapy for gastric diseases. Curr. Gene Ther., 2008, 8(3), 187-200.